Literature DB >> 23222247

A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.

Amanda Segal1, Gregory F Sterrett, Felicity A Frost, Keith B Shilkin, Nola J Olsen, Arthur William Musk, Anna K Nowak, Bruce William S Robinson, Jenette Creaney.   

Abstract

AIMS: Cytological diagnosis of malignant pleural mesothelioma (MPM) is controversial, but has been used in our institution for over 30 years. To assess the role of effusion cytology in mesothelioma diagnosis we conducted an audit of pleural fluid cytology results over a 20 year period (1988-2007).
METHODS: Pleural samples were received from 6285 patients; data linkage with Western Australian Cancer and Mesothelioma Registries demonstrated that 815 of these patients had a diagnosis of MPM. Cytological examination of a pleural effusion specimen had been performed in 517 (63%) of these 815 patients.
RESULTS: Definitive cytological diagnosis of MPM was made in 377/517 cases, resulting in an 'absolute' sensitivity of 73%. An additional 66 patients were diagnosed as atypical/suspicious, resulting in a 'complete' sensitivity of 86%. If only biopsy/necropsy proven cases are considered, the absolute sensitivity is 68% and the complete sensitivity is 82%. There were no false positive diagnoses of malignancy; two patients with metastatic adenocarcinoma were initially diagnosed as MPM, prior to the availability of specific mesothelial markers, resulting in a positive predictive value of 99%.
CONCLUSIONS: Effusion cytology is an inexpensive, minimally invasive procedure which should be included in the diagnostic work-up of cases of suspected MPM.

Entities:  

Mesh:

Year:  2013        PMID: 23222247     DOI: 10.1097/PAT.0b013e32835bc848

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  19 in total

Review 1.  Malignant pleural mesothelioma: an update on diagnosis and treatment options.

Authors:  Sanjana Kondola; David Manners; Anna K Nowak
Journal:  Ther Adv Respir Dis       Date:  2016-02-12       Impact factor: 4.031

Review 2.  The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.

Authors:  Greta Alì; Rossella Bruno; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

3.  Modern day management of a unilateral pleural effusion.

Authors:  Dana Li; Syed Ajmal; Muhammad Tufail; Rakesh K Panchal
Journal:  Clin Med (Lond)       Date:  2021-11       Impact factor: 2.659

4.  Cytological Diagnostic Procedures in Malignant Mesothelioma.

Authors:  Christian Biancosino; Lea Isabell Shari van der Linde; Guido Sauter; Florian Stellmacher; Marcus Krüger; Lutz Welker
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.

Authors:  Filip Mundt; Gustav Nilsonne; Sertaç Arslan; Karola Csürös; Gunnar Hillerdal; Huseyin Yildirim; Muzaffer Metintas; Katalin Dobra; Anders Hjerpe
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

6.  Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.

Authors:  Adam Szulkin; Rita Otvös; Carl-Olof Hillerdal; Aytekin Celep; Eviane Yousef-Fadhel; Henriette Skribek; Anders Hjerpe; László Székely; Katalin Dobra
Journal:  BMC Cancer       Date:  2014-09-24       Impact factor: 4.430

7.  Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.

Authors:  Jenette Creaney; Amanda Segal; Nola Olsen; Ian M Dick; A W Bill Musk; Steven J Skates; Bruce W Robinson
Journal:  Dis Markers       Date:  2014-11-23       Impact factor: 3.434

8.  Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study.

Authors:  Laura Saracino; Chandra Bortolotto; Stefano Tomaselli; Elia Fraolini; Matteo Bosio; Giulia Accordino; Francesco Agustoni; David M Abbott; Emma Pozzi; Dimitrios Eleftheriou; Patrizia Morbini; Pietro Rinaldi; Cristiano Primiceri; Andrea Lancia; Patrizia Comoli; Andrea R Filippi; Giulia M Stella
Journal:  BMC Cancer       Date:  2021-07-01       Impact factor: 4.430

9.  Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.

Authors:  Jenette Creaney; Sophie Sneddon; Ian M Dick; Hanne Dare; Neil Boudville; Arthur William Musk; Steven J Skates; Bruce W S Robinson
Journal:  Dis Markers       Date:  2013-08-06       Impact factor: 3.434

10.  Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

Authors:  Jenette Creaney; Ian M Dick; Tarek M Meniawy; Su Lyn Leong; Justine S Leon; Yvonne Demelker; Amanda Segal; A W Bill Musk; Y C Gary Lee; Steven J Skates; Anna K Nowak; Bruce W S Robinson
Journal:  Thorax       Date:  2014-07-18       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.